Neuraly Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
18
- Latest Deal Type
-
M&A
- Investors
-
1
Neuraly General Information
Description
Operator of a clinical-stage biotechnology company intended to translate scientific discoveries in neurology into new drugs. The company discovers and develops revolutionary treatments for neurodegenerative diseases, and offers a clinical development strategy focusing on the inhibition of pathological glial activation and its role in preventing neuronal cell death, thereby enabling people suffering from the devastating consequences of diseases such as Parkinson's disease (PD), and Alzheimer's disease (AD) to improve their living.
Contact Information
Website
www.neuralymed.com(Operating Subsidiary)
Corporate Office
- 704 Quince Orchard Road
- Suite 320
- Gaithersburg, MD 20878
- United States
Corporate Office
- 704 Quince Orchard Road
- Suite 320
- Gaithersburg, MD 20878
- United States
Neuraly Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 01-Jan-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 18-Jul-2018 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2016 | Completed | Startup |
Neuraly Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 |
Neuraly Patents
Neuraly Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4705331-A1 | Glucagon-like peptide-1 receptor agonist variants and methods thereof | Pending | 01-May-2023 | ||
| US-20260295054-A1 | Glucagon-like peptide-1 receptor agonist variants and methods thereof | Pending | 01-May-2023 | ||
| WO-2024229006-A1 | Glucagon-like peptide-1 receptor agonist variants and methods thereof | Inactive | 01-May-2023 | ||
| US-20240374691-A1 | Glp-1r agonists for use in a treatment of neurologial impairment associated with viral infection | Pending | 25-Aug-2021 | ||
| WO-2023028554-A1 | Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection | Inactive | 25-Aug-2021 | A61K38/26 |
Neuraly Signals
Neuraly Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boston Harbor Angels | Angel Group | Minority | ||
| Dongkoo Bio&Pharma | Corporation | Minority | ||
| Geon Investment | Venture Capital | Minority | ||
| InterVest | Venture Capital | Minority | ||
| Johns Hopkins Technology Ventures | Accelerator/Incubator |
Neuraly Investments (1)
Neuraly’s most recent deal was a Joint Venture with Zentera Alpha. The deal was made on 01-Jan-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zentera Alpha | 01-Jan-2022 | Joint Venture | Drug Discovery |
Neuraly FAQs
-
When was Neuraly founded?
Neuraly was founded in 2016.
-
Where is Neuraly headquartered?
Neuraly is headquartered in Gaithersburg, MD.
-
What is the size of Neuraly?
Neuraly has 18 total employees.
-
What industry is Neuraly in?
Neuraly’s primary industry is Drug Discovery.
-
Is Neuraly a private or public company?
Neuraly is a Private company.
-
What is Neuraly’s current revenue?
The current revenue for Neuraly is .
-
How much funding has Neuraly raised over time?
Neuraly has raised $36M.
-
Who are Neuraly’s investors?
Boston Harbor Angels, Dongkoo Bio&Pharma, Geon Investment, InterVest, and Johns Hopkins Technology Ventures are 5 of 10 investors who have invested in Neuraly.
-
When was Neuraly acquired?
Neuraly was acquired on 01-Jan-2019.
-
Who acquired Neuraly?
Neuraly was acquired by D&D Pharmatech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process